Therapeutic Area Transformation

Finding cures and unleashing value

​Chronic disease and end-of-life care generate costs that are crippling economies. Today, the high cost of care exhausts a huge amount of resources that could otherwise be deployed to fuel more productive economic growth.

How we can help

​Deloitte’s Therapeutic Area Transformation (TAT) practice connects our clients and other industry leaders across sectors to help create innovative, integrated solutions to some of the world’s greatest health care challenges. By working together, we can help meet the needs of a market that is moving from volume to value to drive down health care costs while potentially improving quality and access to care, starting with cancer and diabetes.

Our service offerings include:

  • Therapeutic area strategy and patient journey insights
  • Innovation and exponential based strategic planning for diseases (e.g. oncology, diabetes)
  • Therapeutic area specific real world evidence platforms
  • Translational medicine network programs
  • Advanced digital patient engagement solutions
Download the PDF

Key Potential Benefits

  • Radical reduction of health care costs through innovation
  • Sustainable improvement in patient outcomes and quality of care
  • Discovery of cures for chronic and genomic-based diseases that are available to the average person, regardless of wealth or geography

Meet the leaders

Asif Dhar

Asif Dhar

Principal | Deloitte Consulting LLP

Asif is a principal in Deloitte Consulting LLP's Monitor Deloitte practice. He serves as Chief Health Informatics Officer (CHIO) and helps drive the Therapeutic Area Transformation Integrated offering... More

Beth Meagher

Beth Meagher

Federal Strategy Leader | Deloitte Consulting LLP

Beth is a Deloitte Consulting LLP principal and leader of the Federal Strategy and Translational Medicine practices. Beth focuses on helping the Federal government transform how it views customers; le... More

Dan Ressler

Dan Ressler

Principal | Deloitte Advisory

Dan is a principal in Deloitte Risk and Financial Advisory’s Life Sciences practice, serving as the US Advisory Life Sciences leader. With nearly 25 years of consulting experience in bio-pharmaceutica... More